Amgen’s Otezla (Apremilast) is now Accessible in The US to treat Moderate to Severe Pediatric Plaque Psoriasis
Shots:
- The company has launched Otezla to treat moderate to severe Plaque Pso patients {Age6-17 or wt. 20kg(44lb)} across the US
- Approval was based on the P-III (SPROUT) study that assessed the efficacy & safety of Otezla (20mg, BID, wt. 20-50 kg; 30mg, bid, at least 50 kg wt.) vs PBO. The Study reached its 1EPs at 16 wks. in Otezla vs PBO (33.1% vs 10.8%). Adverse events were constantly the same as adult patients
- Otezla (oral) specifically inhibits the enzyme phosphodiesterase 4 (PDE4), which targets cyclic adenosine monophosphate (cAMP). US FDA approved Otezla for pediatric in April 2024
Ref: Amgen | Image: Amgen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
